

PREVENTION OF HYPERPHOSPHATEMIA
IN KIDNEY DISORDER PATIENTS

Abstract of the Disclosure

The 19-nor-vitamin D analogs, and particularly 19-nor-
5 1 α ,25-dihydroxyvitamin D₂, possess low calcemic and
phosphatemic activity while also having the ability to suppress
parathyroid hormone (PTH) production. The suppressive effect
on PTH secretion of these 19-nor analogs without significant
changes in serum calcium or serum phosphorus make them
10 ideal tools for the treatment of secondary hyperparathyroidism
in patients having kidney disorders.